Does the media favor DHT.UN or CPH?

In the previous week, DRI Healthcare Trust and DRI Healthcare Trust both had 1 articles in the media. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat DRI Healthcare Trust's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DRI Healthcare Trust 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cipher Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CPH or GUD?

In the previous week, Knight Therapeutics had 4 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 5 mentions for Knight Therapeutics and 1 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat Knight Therapeutics' score of 0.45 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cipher Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Knight Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend THCX or CPH?

Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 24.36%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, THCX or CPH?

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hydropothecary N/A N/A N/A N/A N/A Cipher Pharmaceuticals C$49.62M 6.99 C$11.41M C$1.12 12.21

Do analysts prefer CMED or CPH?

Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 24.36%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, CMED or CPH?

Cipher Pharmaceuticals has higher revenue and earnings than CanniMed Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CanniMed Therapeutics N/A N/A N/A N/A N/A Cipher Pharmaceuticals C$49.62M 6.99 C$11.41M C$1.12 12.21

Cipher Pharmaceuticals (CPH) Competitors

C$13.65 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

CPH vs. DHT.UN, GUD, THCX, TLRY, and CMED

Should you buy Cipher Pharmaceuticals stock or one of its competitors? Cipher Pharmaceuticals's main competitors and comparable companies include DRI Healthcare Trust (DHT.UN), Knight Therapeutics (GUD), Hydropothecary (THCX), Tilray Brands (TLRY), and CanniMed Therapeutics (CMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

DRI Healthcare Trust presently has a consensus price target of C$25.60, indicating a potential upside of 39.59%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 24.36%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, equities research analysts plainly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DRI Healthcare Trust has a beta of 0.365327, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.045899, meaning that its stock price is 5% more volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 22.74% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

In the previous week, DRI Healthcare Trust and DRI Healthcare Trust both had 1 articles in the media. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat DRI Healthcare Trust's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DRI Healthcare Trust	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cipher Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cipher Pharmaceuticals has lower revenue, but higher earnings than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$172.34M	5.85	C$9.73M	-C$0.80	N/A
Cipher Pharmaceuticals	C$49.62M	6.99	C$11.41M	C$1.12	12.21

0.8% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 11 of the 16 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Cipher Pharmaceuticals (TSE:CPH) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Cipher Pharmaceuticals has a beta of 1.045899, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, indicating that its stock price is 129% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Knight Therapeutics' net margin of 2.72%. Cipher Pharmaceuticals' return on equity of 22.74% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Knight Therapeutics	2.72%	1.91%	0.51%

In the previous week, Knight Therapeutics had 4 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 5 mentions for Knight Therapeutics and 1 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat Knight Therapeutics' score of 0.45 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Knight Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	6.99	C$11.41M	C$1.12	12.21
Knight Therapeutics	C$547.31M	1.88	-C$30.73M	C$0.15	69.67

Cipher Pharmaceuticals presently has a consensus price target of C$17.00, indicating a potential upside of 24.36%. Knight Therapeutics has a consensus price target of C$9.50, indicating a potential downside of 9.09%. Given Cipher Pharmaceuticals' higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Hydropothecary. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Hydropothecary. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat Hydropothecary's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Hydropothecary	Neutral
Cipher Pharmaceuticals	Positive

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 22.74% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	C$49.62M	6.99	C$11.41M	C$1.12	12.21

Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 24.36%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cipher Pharmaceuticals beats Hydropothecary on 10 of the 10 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Cipher Pharmaceuticals (TSE:CPH) and Tilray Brands (TSE:TLRY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Tilray Brands. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Tilray Brands. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat Tilray Brands' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Positive
Tilray Brands	Neutral

Cipher Pharmaceuticals has a beta of 1.045899, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.215277, suggesting that its share price is 222% more volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	6.99	C$11.41M	C$1.12	12.21
Tilray Brands	C$915.45M	0.82	-C$183.24M	-C$1.09	N/A

Cipher Pharmaceuticals has a net margin of 58.81% compared to Tilray Brands' net margin of -15.22%. Cipher Pharmaceuticals' return on equity of 22.74% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Tilray Brands	-15.22%	-8.85%	-1.41%

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, indicating a potential upside of 24.36%. Tilray Brands has a consensus target price of C$13.30, indicating a potential upside of 161.81%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.7% of Tilray Brands shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cipher Pharmaceuticals beats Tilray Brands on 10 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 24.36%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has higher revenue and earnings than CanniMed Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	C$49.62M	6.99	C$11.41M	C$1.12	12.21

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for CanniMed Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 0.75 beat CanniMed Therapeutics' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CanniMed Therapeutics	Neutral
Cipher Pharmaceuticals	Positive

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a net margin of 58.81% compared to CanniMed Therapeutics' net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 22.74% beat CanniMed Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CanniMed Therapeutics	N/A	N/A	N/A
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Summary

Cipher Pharmaceuticals beats CanniMed Therapeutics on 10 of the 10 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$346.59M	C$12.18B	C$7.09B	C$12.53B
Dividend Yield	N/A	2.63%	2.53%	6.31%
P/E Ratio	12.19	797.15	274.61	39.33
Price / Sales	6.98	751.64	600.51	9.16
Price / Cash	3.53	81.79	77.38	82.29
Price / Book	2.53	10.47	10.92	4.61
Net Income	C$11.41M	C$2.83B	C$3.50B	C$299.09M
7 Day Performance	-1.73%	-1.65%	-2.11%	-1.15%
1 Month Performance	-6.12%	-5.77%	-6.34%	-2.15%
1 Year Performance	-15.69%	-3.80%	8.81%	17.09%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	3.1914 of 5 stars	C$13.65 flat	C$17.00 +24.5%	-12.3%	C$346.59M	C$49.62M	12.19	5
DHT.UN DRI Healthcare Trust	1.763 of 5 stars	C$18.37 +1.3%	C$25.60 +39.4%	+24.5%	C$1.01B	C$172.34M	N/A	N/A
GUD Knight Therapeutics	0.7671 of 5 stars	C$10.10 +0.1%	C$9.50 -5.9%	+79.4%	C$992.14M	C$547.31M	67.33	830
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
TLRY Tilray Brands	1.1944 of 5 stars	C$5.76 -0.7%	C$13.30 +130.9%	-77.8%	C$808.84M	C$915.45M	N/A	3,595

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. DHT.UN, GUD, THCX, TLRY, and CMED

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. DHT.UN, GUD, THCX, TLRY, and CMED

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Do analysts prefer DHT.UN or CPH?

Which has more volatility & risk, DHT.UN or CPH?

Is DHT.UN or CPH more profitable?

Does the media favor DHT.UN or CPH?

Which has stronger valuation and earnings, DHT.UN or CPH?

Do insiders and institutionals believe in DHT.UN or CPH?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Which has more volatility and risk, CPH or GUD?

Is CPH or GUD more profitable?

Does the media refer more to CPH or GUD?

Do institutionals and insiders have more ownership in CPH or GUD?

Which has preferable valuation and earnings, CPH or GUD?

Do analysts rate CPH or GUD?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Does the media refer more to THCX or CPH?

Do insiders & institutionals hold more shares of THCX or CPH?

Is THCX or CPH more profitable?

Which has stronger valuation and earnings, THCX or CPH?

Do analysts recommend THCX or CPH?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Does the media refer more to CPH or TLRY?

Which has more volatility & risk, CPH or TLRY?

Which has preferable valuation and earnings, CPH or TLRY?

Is CPH or TLRY more profitable?

Do analysts prefer CPH or TLRY?

Do insiders & institutionals have more ownership in CPH or TLRY?

Summary

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

Do analysts prefer CMED or CPH?

Which has stronger valuation and earnings, CMED or CPH?

Does the media favor CMED or CPH?

Do insiders & institutionals hold more shares of CMED or CPH?

Is CMED or CPH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools